Enliven Therapeutics, Inc. · NASDAQ:ELVN
Orbimed Advisors LLC sold 860,123 Enliven Therapeutics, Inc. shares (Form 4)
Traded Jun 22, 2026 · Filed Jun 24, 2026
On Jun 22, 2026, Orbimed Advisors LLC (10% owner) sold 860,123 Enliven Therapeutics, Inc. shares at an average US$45.36 for US$39M, leaving 6,555,102 shares. Filed Jun 24, 2026 (Form 4).
- Sold
- 860,123 shares
- Price
- US$45.36 average (US$45.00 to US$45.38)
- Value
- US$39M
- Holding after
- 6,555,102 shares (held indirectly)
- Trading plan
- No
- Role
- 10% owner
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jun 22, 2026 | Common Stock | Sale | 24,846 | US$45.38 | 220,882 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 1,477 | US$45.00 | 219,405 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 787,024 | US$45.38 | 6,601,878 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 46,776 | US$45.00 | 6,555,102 | Indirect |
Source
Related
- Enliven Therapeutics, Inc.
- Orbimed Advisors LLC
- Enliven Therapeutics, Inc. shareholders
- Form 4 · Orbimed Advisors LLC · Jun 17, 2026
- Form 4 · Hohl Benjamin · Oct 21, 2026
- Form 4 · Collins Helen Louise · Oct 21, 2026
- Form 4 · Garland J. Scott · Oct 5, 2026
- Form 4 · Hohl Benjamin · Sep 21, 2026
- Form 4 · Collins Helen Louise · Sep 21, 2026